GALNT14-rs9679162 Genotypes Predict Post-immunotherapy Side Effect and Survival in Patients with Hepatitis B Virus-related Hepatocellular Carcinoma.

IF 3.4 3区医学 Q2 ONCOLOGY

Journal of Cancer Pub Date : 2026-06-10 eCollection Date: 2026-01-01 DOI:10.7150/jca.133473

Po-Ting Lin, Wei Teng, Wei-Ting Chen, Yu-De Chu, Chung-Wei Su, Yi-Chung Hsieh, Chen-Chun Lin, Yung-Chang Lin, Chun-Yen Lin, Chau-Ting Yeh, Shi-Ming Lin

{"title":"GALNT14-rs9679162 Genotypes Predict Post-immunotherapy Side Effect and Survival in Patients with Hepatitis B Virus-related Hepatocellular Carcinoma.","authors":"Po-Ting Lin, Wei Teng, Wei-Ting Chen, Yu-De Chu, Chung-Wei Su, Yi-Chung Hsieh, Chen-Chun Lin, Yung-Chang Lin, Chun-Yen Lin, Chau-Ting Yeh, Shi-Ming Lin","doi":"10.7150/jca.133473","DOIUrl":null,"url":null,"abstract":"Introduction: Genomic alterations have been reported to correlate with patients' response to immune checkpoint inhibitor (ICI) therapy in hepatocellular carcinoma (HCC). The present study aimed to examine whether single nucleotide polymorphism (SNP) is associated with ICI treatment-related side effects and progression-free survival (PFS) in HCC patients.Methods: This retrospective study included 96 patients with HBV-related HCC receiving ICI (atezolizumab plus bevazizumab) therapy between 2020 and 2023. Five SNPs derived from a previous genome-wide association study linking to chemotherapy responses in HCC patients were included. Their predictive values for PFS and side effects were examined.Results: After ICI therapy, patients with GALNT14-rs9679162 \"GG\" genotype (median PFS = 19.7 months, 95% confidence interval [CI]: 12.3-35.7; p = 0.032) had a longer PFS, whereas GALNT14-rs675230, BMP7-rs6025211, WWOX-rs13338697 or WWOX-rs13333314 were not associated with PFS (all p > 0.05). GALNT14-rs9679162 \"GG\" genotype (odds ratio [OR] = 0.298, 95% CI: 0.096-0.926; p = 0.036) was also associated with a decreased risk of post-treatment high-grade aspartate aminotransferase (AST) elevation. Multivariate analysis showed that GALNT14-rs9679162 \"GG\" genotype (hazard ratio [HR] = 0.433, 95% CI: 0.212-0.886; p = 0.022) and high initial albumin-bilirubin (ALBI) grade (HR = 2.053, 95% CI: 1.153-3.590; p = 0.014) were independently associated with PFS.Conclusions: Genetic variant of an SNP, GALNT14-rs9679162, predicts post-treatment PFS and side effect in HBV-related HCC patients receiving ICIs therapy.","PeriodicalId":15183,"journal":{"name":"Journal of Cancer","volume":"17 6","pages":"1220-1228"},"PeriodicalIF":3.4000,"publicationDate":"2026-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13280630/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7150/jca.133473","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Genomic alterations have been reported to correlate with patients' response to immune checkpoint inhibitor (ICI) therapy in hepatocellular carcinoma (HCC). The present study aimed to examine whether single nucleotide polymorphism (SNP) is associated with ICI treatment-related side effects and progression-free survival (PFS) in HCC patients.

Methods: This retrospective study included 96 patients with HBV-related HCC receiving ICI (atezolizumab plus bevazizumab) therapy between 2020 and 2023. Five SNPs derived from a previous genome-wide association study linking to chemotherapy responses in HCC patients were included. Their predictive values for PFS and side effects were examined.

Results: After ICI therapy, patients with GALNT14-rs9679162 "GG" genotype (median PFS = 19.7 months, 95% confidence interval [CI]: 12.3-35.7; p = 0.032) had a longer PFS, whereas GALNT14-rs675230, BMP7-rs6025211, WWOX-rs13338697 or WWOX-rs13333314 were not associated with PFS (all p > 0.05). GALNT14-rs9679162 "GG" genotype (odds ratio [OR] = 0.298, 95% CI: 0.096-0.926; p = 0.036) was also associated with a decreased risk of post-treatment high-grade aspartate aminotransferase (AST) elevation. Multivariate analysis showed that GALNT14-rs9679162 "GG" genotype (hazard ratio [HR] = 0.433, 95% CI: 0.212-0.886; p = 0.022) and high initial albumin-bilirubin (ALBI) grade (HR = 2.053, 95% CI: 1.153-3.590; p = 0.014) were independently associated with PFS.

Conclusions: Genetic variant of an SNP, GALNT14-rs9679162, predicts post-treatment PFS and side effect in HBV-related HCC patients receiving ICIs therapy.

查看原文本刊更多论文

GALNT14-rs9679162基因型预测乙型肝炎病毒相关肝细胞癌患者免疫治疗后副作用和生存

基因组改变已被报道与肝细胞癌（HCC）患者对免疫检查点抑制剂（ICI）治疗的反应相关。本研究旨在探讨HCC患者的单核苷酸多态性（SNP）是否与ICI治疗相关的副作用和无进展生存期（PFS）相关。方法：这项回顾性研究纳入了96例在2020年至2023年间接受ICI （atezolizumab + bevazizumab）治疗的hbv相关HCC患者。5个snp来自先前的全基因组关联研究，与HCC患者化疗反应相关。研究了它们对PFS和副作用的预测价值。结果：在ICI治疗后，GALNT14-rs9679162“GG”基因型患者（中位PFS = 19.7个月，95%可信区间[CI]: 12.3-35.7; p = 0.032）的PFS较长，而GALNT14-rs675230、BMP7-rs6025211、WWOX-rs13338697或WWOX-rs13333314与PFS无相关性（均p < 0.05）。GALNT14-rs9679162“GG”基因型（优势比[OR] = 0.298, 95% CI: 0.096-0.926; p = 0.036）也与治疗后高级别天冬氨酸转氨酶（AST）升高的风险降低相关。多因素分析显示GALNT14-rs9679162“GG”基因型（风险比[HR] = 0.433, 95% CI: 0.212-0.886; p = 0.022）和高初始白蛋白-胆红素（ALBI）分级（HR = 2.053, 95% CI: 1.153-3.590; p = 0.014）与PFS独立相关。结论：GALNT14-rs9679162 SNP的遗传变异可预测接受ICIs治疗的hbv相关HCC患者的治疗后PFS和副作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Cancer ONCOLOGY-

CiteScore

8.10

自引率

2.60%

发文量

333

审稿时长

12 weeks

期刊介绍： Journal of Cancer is an open access, peer-reviewed journal with broad scope covering all areas of cancer research, especially novel concepts, new methods, new regimens, new therapeutic agents, and alternative approaches for early detection and intervention of cancer. The Journal is supported by an international editorial board consisting of a distinguished team of cancer researchers. Journal of Cancer aims at rapid publication of high quality results in cancer research while maintaining rigorous peer-review process.